On January 19th, Red Star Capital Bureau reported that according to the official website of the Shanghai Municipal Administration for Market Regulation, Baekje Shenzhou (Shanghai) Biotechnology Co., Ltd. (hereinafter referred to as "Baekje Shenzhou Biotechnology") has recently been fined 400000 yuan for using advertisements to falsely promote goods or services.
After investigation, it was found that BeiGene Biotech was entrusted by BeiGene (688235. SH; 06160. HK; BGNE. US) to be responsible for the marketing of Pamipali capsules. However, according to public information, there is currently no equity relationship between the two companies.
On January 19th, BeiGene responded to the Red Star Capital Bureau that the company would take it as a warning and strictly comply with relevant laws and regulations in its future work.
On August 18, 2022, BeiGene Biotech held the "Baihuize City Conference" and during the conference, published an advertisement for Pamipali capsules in public areas using a flip flop and promotional flyer as carriers, claiming that "Baihuize (Pamipali) is the only PARP inhibitor approved for the treatment of 3L gBRCAm platinum sensitive and platinum resistant recurrent ovarian cancer; CGCS guidelines recommend Pamipali as the preferred drug for the treatment of recurrent ovarian cancer; the monthly treatment cost for medical insurance patients is only 1929 yuan.".
Data shows that Pamipali capsules are used for the treatment of recurrent advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer patients who have undergone second-line or above chemotherapy and have germline BRCA (gBRCA) mutations.
But as a prescription drug, it can only be advertised in medical and pharmaceutical professional journals jointly designated by the health administrative department of the State Council and the drug regulatory department of the State Council.
On September 21, 2022, with approval, an investigation was filed into the illegal advertising behavior of BeiGene Biotech.
The Market Supervision Administration of Jing'an District, Shanghai believes that Baekje Shenzhou Biotechnology promotes the above-mentioned prescription drugs in public places through the form of pull-up banners and promotional leaflets. The advertising target audience is not specific and will have an impact on the choices of ordinary patients and consumers without professional medical and pharmaceutical knowledge. It cannot guarantee the scientific, correct, reasonable, and safe use of drugs. Finally, BeiGene Biotech received the Administrative Penalty Hearing Notice on December 27, 2023.
Red Star News reporter Deng Lingyao